Artemis Therapeutics Appoints Brian M. Culley As Chief Executive Officer

NEW YORK, Oct. 26, 2017 /PRNewswire/ -- Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a clinical-stage biopharmaceutical company developing new therapies for the treatment and prevention of severe and life-threatening infectious diseases, announced today the appointment of Brian M. Culley, M.A., M.B.A. as its Chief Executive Officer. Mr. Culley is an entrepreneurial and innovative biotech executive with 25 years of experience, spanning diverse operational areas including strategy, finance, licensing, and clinical development.

"I am excited to help Artemis achieve rapid growth by advancing its drug development programs into clinical trials. I believe my experience building the teams, infrastructure, and institutional awareness necessary to advance drug candidates through clinical development, as well as my close involvement with patient and advocacy groups, will increase our value and visibility within the investment and disease communities," stated Mr. Culley. "Our initial focus is to develop Artemisone as a superior treatment option for life-threatening diseases such as malaria and cytomegalovirus (CMV). These diseases impair global health and economics and require urgent action, as current treatments are limited by toxicity and resistance concerns. Meanwhile, millions of lives in the U.S. and around the world are being impacted, most of them children. We are encouraged by the preliminary results we have seen in clinical and non-clinical studies in these two diseases and our progress with Artemisone is accelerated due to extensive development and clinical work conducted by Bayer HealthCare and our two academic partners. Artemisone will provide a robust foundation for the Company's growth and we look forward to providing investors with a roadmap of milestones from which to monitor our progress."

Most recently, Mr. Culley served as Chief Executive Officer and as a member of the board of directors of Mast Therapeutics, a publicly-held, clinical stage biopharmaceutical company, which was acquired in April 2017 by Savara. During his tenure as CEO, Mr. Culley grew the company from two to 50 employees and internal consultants, oversaw clinical development of multiple mid- and late-stage product candidates in hematology/oncology and cardio-renal indications, ran the largest interventional trial ever-completed in sickle cell disease, and expanded the company's development pipeline via three acquisitions, including Aries Pharmaceuticals, which contributed to the acquisition of Aironite by Savara. He is a member of the Board of Directors of Orphagen Pharmaceuticals.

Mr. Culley's earlier experience includes operational roles in business development for Immusol, technology transfer for the University of California San Diego, and as a research scientist for Neurocrine Biosciences. He received a B.S. in biology from Boston College, a masters in biochemistry from the University of California, Santa Barbara and an M.B.A. from The Johnson School of Business at Cornell University.

About Artemis Therapeutics
Artemis Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The Company's lead product candidate, Artemisone, is a unique, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties. The Company is evaluating Artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (CMV) infection, including stem cell transplant CMV and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic diseases. More information is available on the Company's website: www.artemis-therapeutics.com and Twitter: @ArtemisThera.

Forward Looking Statements:
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Investor Relations
([email protected])

SOURCE Artemis Therapeutics, Inc.

Related Links

http://artemis-therapeutics.com